Hi-Puri™ Human Anti-Human FZD monoclonal antibody, clone F2.I

Name: Hi-Puri™ Human Anti-Human FZD monoclonal antibody, clone F2.I
SKU: DMABB-JXR28
Rating: 5 (1 reviews)

Human Anti-Human FZD monoclonal antibody for ELISA, Inhib, FuncS

COA

SDS

Datasheet

Key features and details

Binds to human FZD1, -2, -4, -5, -7, and -8, but did not binds FZD3, -6, -9, or -10.
Has cross-reactivity with mouse FZD4 and FZD5.
Functionally inhibited Wnt3a-induced β-catenin stabilization.
Isotype: IgG
Clonality: Monoclonal
Various conjugated forms available upon request.

Summary

Specifications

Antibody Isotype

IgG

Clone

F2.I

Species Reactivity

Human; Mouse

Immunogen

The original antibody was obtained by phage display experiments.

Conjugate

Unconjugated

Applications

Application Notes

ELISA, Inhib, FuncS
Each laboratory should determine an optimum working titer for use in its particular application.
Other applications have not been tested but use in such assays should not necessarily be excluded.

General Notes

Clone F2.I and F7.B bind to FZD1, -2, -4, -5, -7, and -8 on the cell surface, but did not bind FZD3, -6, -9, or -10 at the tested concentrations. Clone F6 bound FZD1, -2, -5, -7, and -8, but not FZD4. F6, F2.I, and F7.B showed cross-reactivity to mouse FZD4 and FZD5 (within the CRD region, human and mouse FZD4 and FZD5 have a 96.7% and 98.4% homology, respectively, and all other relevant FZD receptors are 100% homologous between mouse and human). These threee Abs bind to overlapping epitopes on FZD–CRD.

Target

Alternative Names

frizzled class receptor; frizzled receptor; frizzled; frizzled-1; frizzled-2; frizzled-3; frizzled-4; frizzled-5; frizzled-6; frizzled-7; frizzled-8; frizzled-9; frizzled-10; FZD1; FZD2; FZD3; FZD4; FZD5; FZD6; FZD7; FZD8; FZD9; FZD10

Citations

Have you cited DMABB-JXR28 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.

Proc Natl Acad Sci U S A 116: 6812-6817

Authors: Raman, S., et al. (2019).

Abstract

Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.